HRP20201644T1 - Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba - Google Patents

Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba Download PDF

Info

Publication number
HRP20201644T1
HRP20201644T1 HRP20201644TT HRP20201644T HRP20201644T1 HR P20201644 T1 HRP20201644 T1 HR P20201644T1 HR P20201644T T HRP20201644T T HR P20201644TT HR P20201644 T HRP20201644 T HR P20201644T HR P20201644 T1 HRP20201644 T1 HR P20201644T1
Authority
HR
Croatia
Prior art keywords
compound
formula
crystalline
crystalline form
crystal form
Prior art date
Application number
HRP20201644TT
Other languages
English (en)
Croatian (hr)
Inventor
Zhaozhong DING
Fei Sun
Yinghu HU
Yilong ZHOU
Zheng Wang
Rui Zhao
Ling Yang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. filed Critical Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Publication of HRP20201644T1 publication Critical patent/HRP20201644T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20201644TT 2016-02-05 2017-02-04 Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba HRP20201644T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610082029.8A CN107043379A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的晶型a、其制备方法和医药用途
PCT/CN2017/072891 WO2017133684A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的晶型a、其制备方法和用途
EP17747004.4A EP3412672B1 (en) 2016-02-05 2017-02-04 Crystal form a of 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl) benzyl)-5h-pyrrolo[3,2-d]pyrimidin-4-amine as tlr7 agonist, preparation method and use thereof

Publications (1)

Publication Number Publication Date
HRP20201644T1 true HRP20201644T1 (hr) 2020-12-25

Family

ID=59499348

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201644TT HRP20201644T1 (hr) 2016-02-05 2017-02-04 Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba

Country Status (27)

Country Link
US (2) US10442811B2 (cg-RX-API-DMAC7.html)
EP (1) EP3412672B1 (cg-RX-API-DMAC7.html)
JP (1) JP6889171B2 (cg-RX-API-DMAC7.html)
KR (1) KR102393280B1 (cg-RX-API-DMAC7.html)
CN (2) CN107043379A (cg-RX-API-DMAC7.html)
AR (1) AR107548A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017215801B2 (cg-RX-API-DMAC7.html)
CA (1) CA3013518C (cg-RX-API-DMAC7.html)
CL (1) CL2018002092A1 (cg-RX-API-DMAC7.html)
DK (1) DK3412672T3 (cg-RX-API-DMAC7.html)
EA (1) EA035951B1 (cg-RX-API-DMAC7.html)
ES (1) ES2830443T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201644T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051399T2 (cg-RX-API-DMAC7.html)
IL (1) IL260968B (cg-RX-API-DMAC7.html)
LT (1) LT3412672T (cg-RX-API-DMAC7.html)
MX (1) MX374297B (cg-RX-API-DMAC7.html)
NZ (1) NZ744884A (cg-RX-API-DMAC7.html)
PH (1) PH12018501643A1 (cg-RX-API-DMAC7.html)
PL (1) PL3412672T3 (cg-RX-API-DMAC7.html)
PT (1) PT3412672T (cg-RX-API-DMAC7.html)
SG (1) SG11201806683UA (cg-RX-API-DMAC7.html)
SI (1) SI3412672T1 (cg-RX-API-DMAC7.html)
TW (1) TWI754629B (cg-RX-API-DMAC7.html)
UA (1) UA121161C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017133684A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805186B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN107043378A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CA3101370A1 (en) * 2018-05-25 2019-11-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
EP3937944A1 (en) 2019-03-15 2022-01-19 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd Toll-like receptor agonists for use in the treatment of hepatitis b
CA3137202A1 (en) * 2019-04-23 2020-10-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Solid pharmaceutical composition comprising tlr7 agonist
US20230100429A1 (en) 2020-03-02 2023-03-30 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
JP7690222B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むmRNAワクチン
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
CA2826295C (en) * 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) * 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
EP2906563B1 (en) * 2012-10-10 2018-02-28 Janssen Sciences Ireland UC Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
JP6216386B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 新規化合物
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
SG11201503282RA (en) * 2012-11-20 2015-06-29 Glaxosmithkline Llc Novel compounds
MX362341B (es) * 2014-05-01 2019-01-11 Novartis Ag Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX386981B (es) * 2014-08-15 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
SG11201806683UA (en) 2018-09-27
BR112018015880A2 (pt) 2018-12-26
US10947245B2 (en) 2021-03-16
PL3412672T3 (pl) 2021-01-25
UA121161C2 (uk) 2020-04-10
EP3412672A4 (en) 2019-07-17
CN108602831B (zh) 2020-11-03
DK3412672T3 (da) 2020-10-19
HUE051399T2 (hu) 2021-03-01
EA201891768A1 (ru) 2019-01-31
EP3412672B1 (en) 2020-07-15
HK1259170A1 (zh) 2019-11-29
CN108602831A (zh) 2018-09-28
MX2018009501A (es) 2018-12-11
CA3013518C (en) 2022-07-19
CA3013518A1 (en) 2017-08-10
AU2017215801B2 (en) 2020-09-10
JP2019505533A (ja) 2019-02-28
KR20180104117A (ko) 2018-09-19
AR107548A1 (es) 2018-05-09
CL2018002092A1 (es) 2018-12-07
NZ744884A (en) 2022-09-30
AU2017215801A1 (en) 2018-08-23
TW201728589A (zh) 2017-08-16
MX374297B (es) 2025-03-06
PT3412672T (pt) 2020-11-11
US10442811B2 (en) 2019-10-15
LT3412672T (lt) 2020-11-10
US20190040071A1 (en) 2019-02-07
EA035951B1 (ru) 2020-09-04
SI3412672T1 (sl) 2021-02-26
ZA201805186B (en) 2024-08-28
KR102393280B1 (ko) 2022-05-02
US20200039988A1 (en) 2020-02-06
CN107043379A (zh) 2017-08-15
JP6889171B2 (ja) 2021-06-18
PH12018501643A1 (en) 2019-06-03
ES2830443T3 (es) 2021-06-03
EP3412672A1 (en) 2018-12-12
WO2017133684A1 (zh) 2017-08-10
IL260968B (en) 2022-05-01
TWI754629B (zh) 2022-02-11
CN108602831B9 (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
HRP20201644T1 (hr) Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba
HRP20201275T1 (hr) Kristalni oblik derivata benzimidazola i postupak njegove proizvodnje
HRP20160208T4 (hr) Polimorfi dasatiniba i postupak za njihovu pripremu
HRP20141137T1 (hr) Polimorfni oblici macrocikliäśkog inhibitora hcv
BRPI0807319B1 (pt) Base de minociclina cristalina forma 1, processo para preparar base de minociclina cristalina forma i, base de minociclina cristalina forma ii, processo para preparar base de minociclina cristalina forma ii, base de minociclina cristalina forma iii e processo para preparar base de minociclina cristalina forma iii
HRP20240304T1 (hr) Soli valbenazin dihidroklorida i njihovi polimorfi
HRP20160168T1 (hr) Kristalne forme makrolida i njihova uporaba
JP2019505533A5 (cg-RX-API-DMAC7.html)
RU2018145948A (ru) Кристалл пирролопиримидина для получения jak-ингибитора
JP2015522644A5 (cg-RX-API-DMAC7.html)
JP2019504103A5 (cg-RX-API-DMAC7.html)
AU2006301708B2 (en) Glycyrrhetinic acid-30-amide derivatives and the uses thereof
CN101139325A (zh) 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸晶型及其制备方法
JP2022535870A (ja) Cdk9阻害剤の結晶多形体及びその製造方法と用途
HRP20151343T1 (hr) Agomelatin hidrobromid hidrat i njegova priprema
JP2022060192A5 (cg-RX-API-DMAC7.html)
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
WO2018185711A1 (en) Solvates of eluxadoline
HRP20211379T1 (hr) Kristalni oblik antagonista gnrh receptora i postupak njegovog dobivanja
CN104086544B (zh) 阿哌沙班一水合物及其制备方法和药物组合物
CZ305213B6 (cs) Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
TWI824626B (zh) Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
JP2016533361A (ja) ピラゾロピリジン化合物の固体形態
CN103709140A (zh) 泮托拉唑钠的晶体及其制备方法
JP6072908B2 (ja) 重水素化ω―ジメチル尿素又はその塩の多形物